552 SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models

• Yuhong Zhang,
• Akito Nakamura,
• Keli Song,
• Stephen Grossman,
• Kristina Xega,
• Allison Berger,
• Gary Shapiro,
• Dennis Huszar

Affiliations

Yuhong Zhang

School of Public Health, Ningxia Medical University, Yinchuan, China

Akito Nakamura

Takeda Pharmaceuticals, Cambridge, MA, USA

Keli Song

Takeda Pharmaceuticals, Cambridge, MA, USA

Stephen Grossman

Takeda Pharmaceuticals, Cambridge, MA, USA

Kristina Xega

Takeda Pharmaceuticals, Cambridge, MA, USA

Allison Berger

Takeda Pharmaceuticals, Cambridge, MA, USA

Gary Shapiro

Takeda Pharmaceuticals, Cambridge, MA, USA

Dennis Huszar

Takeda Pharmaceuticals, Cambridge, MA, USA